ATE240115T1 - Zusammensetzung zur vorbeugung und/oder behandlung der atherosklerose - Google Patents

Zusammensetzung zur vorbeugung und/oder behandlung der atherosklerose

Info

Publication number
ATE240115T1
ATE240115T1 AT99970026T AT99970026T ATE240115T1 AT E240115 T1 ATE240115 T1 AT E240115T1 AT 99970026 T AT99970026 T AT 99970026T AT 99970026 T AT99970026 T AT 99970026T AT E240115 T1 ATE240115 T1 AT E240115T1
Authority
AT
Austria
Prior art keywords
composition
preventing
low density
density lipoprotein
treating atherosclerosis
Prior art date
Application number
AT99970026T
Other languages
English (en)
Inventor
Yehuda Shoenfeld
Dror Harats
Jacob George
Original Assignee
Vascular Biogenics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vascular Biogenics Ltd filed Critical Vascular Biogenics Ltd
Application granted granted Critical
Publication of ATE240115T1 publication Critical patent/ATE240115T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pretreatment Of Seeds And Plants (AREA)
  • Paints Or Removers (AREA)
  • Medicines Containing Plant Substances (AREA)
AT99970026T 1998-10-04 1999-09-30 Zusammensetzung zur vorbeugung und/oder behandlung der atherosklerose ATE240115T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL12644798A IL126447A (en) 1998-10-04 1998-10-04 An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
PCT/IL1999/000519 WO2000020019A2 (en) 1998-10-04 1999-09-30 A composition for the prevention and/or treatment of atherosclerosis

Publications (1)

Publication Number Publication Date
ATE240115T1 true ATE240115T1 (de) 2003-05-15

Family

ID=11072009

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99970026T ATE240115T1 (de) 1998-10-04 1999-09-30 Zusammensetzung zur vorbeugung und/oder behandlung der atherosklerose

Country Status (16)

Country Link
US (2) US20030114367A1 (de)
EP (1) EP1126867B1 (de)
JP (1) JP4834219B2 (de)
KR (1) KR100680707B1 (de)
CN (2) CN100430090C (de)
AT (1) ATE240115T1 (de)
AU (1) AU760582B2 (de)
BR (1) BR9914631A (de)
CA (1) CA2345445C (de)
DE (1) DE69907945T2 (de)
DK (1) DK1126867T3 (de)
ES (1) ES2198163T3 (de)
HU (1) HUP0104410A3 (de)
IL (1) IL126447A (de)
PT (1) PT1126867E (de)
WO (1) WO2000020019A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100361933B1 (ko) 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
US6858210B1 (en) 1998-06-09 2005-02-22 La Jolla Pharmaceutical Co. Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
US20050197283A1 (en) * 1998-10-04 2005-09-08 Vascular Biogenics Ltd. Compositions containing beta 2-glycoprotein I for the prevention and/or treatment of vascular disease
US6458953B1 (en) * 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
CA2313899A1 (en) * 1999-07-16 2001-01-16 Enzo Therapeutics, Inc. Novel selective imune down regulation (sidr) mediated transplantation processes, processes for preventing or treating diseases in a subject, and compositions of matter comprising trained or programmed cells, tissues or organs useful for sidr establishment
JP2004501061A (ja) * 1999-12-15 2004-01-15 ペプトル・リミテツド 熱ショックタンパク質６０のフラグメントおよびアンタゴニスト
US6812205B2 (en) 2000-03-15 2004-11-02 The Brigham & Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
CA2414076A1 (en) 2000-06-08 2001-12-13 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
FR2816060A1 (fr) * 2000-10-27 2002-05-03 Pf Medicament Procede d'identification de nouvelles molecules se liant au recepteur lox et utilisation de ces molecules
GB0028122D0 (en) * 2000-11-17 2001-01-03 St Georges Entpr Ltd Method
JP4191997B2 (ja) 2001-01-04 2008-12-03 ヴァスキュラー バイオジェニックス リミテッド アテローム性動脈硬化を防止および処置するために斑関連分子を用いる方法および斑関連分子を含有する組成物
SE0103754L (sv) * 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
US20030077279A1 (en) * 2001-10-24 2003-04-24 Cedars-Sinai Medical Center Methods for treating vascular disease by inhibiting toll-like receptor-4
WO2003099833A2 (en) * 2002-05-17 2003-12-04 Board Of Regents, The University Of Texas System Beta-2-glycoprotein 1 is an inhibitor of angiogenesis
GB0226105D0 (en) * 2002-11-08 2002-12-18 St Georges S Entpr Ltd Pain relief agents
US7264813B2 (en) * 2003-09-24 2007-09-04 Nikken Sohonsha Corporation Therapeutic uses of Dunaliella powder
EP1676602A1 (de) * 2005-01-04 2006-07-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Kontinuierlicheverabreichung von Epitope aus dem atherosklerotischem Belag zur Behandlung von Atheriosklerose
CN101146826A (zh) * 2005-01-24 2008-03-19 得克萨斯大学体系董事会 与磷脂酰丝氨酸结合的fc融合构建体及其治疗用途
JP2009515929A (ja) * 2005-11-14 2009-04-16 ネステク ソシエテ アノニム 糖化タンパク質を用いた経口免疫寛容促進
US8961982B2 (en) * 2005-12-16 2015-02-24 The Regents Of The University Of California Modulation of developmental immune programming and protection against cardiovascular disease, diabetes, infectious diseases, and cancer
CA2758213C (en) * 2008-04-10 2017-08-15 Thrombosis Research Institute Anti-atheroma vaccine
US9512196B2 (en) 2008-09-22 2016-12-06 Cedars-Sinai Medical Center Short-form human MD-2 as a negative regulator of toll-like receptor 4 signaling
EP2328911A4 (de) 2008-09-22 2012-03-14 Cedars Sinai Medical Center Kurzes menschliches md-2 als negativer regulator der toll-like-rezeptor-4-signalisierung
CN103185801B (zh) * 2011-12-30 2015-04-15 深圳市亚辉龙生物科技有限公司 一种检测抗β2糖蛋白I抗体的试剂装置及其方法

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3561444A (en) * 1968-05-22 1971-02-09 Bio Logics Inc Ultrasonic drug nebulizer
US3993073A (en) * 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
US3948262A (en) * 1969-04-01 1976-04-06 Alza Corporation Novel drug delivery device
US3699963A (en) * 1969-10-31 1972-10-24 Alza Corp Therapeutic adhesive patch
US3703173A (en) * 1970-12-31 1972-11-21 Ted A Dixon Nebulizer and tent assembly
US3944064A (en) * 1973-10-26 1976-03-16 Alza Corporation Self-monitored device for releasing agent at functional rate
US5869534A (en) * 1992-05-21 1999-02-09 The Picower Institute For Medical Research Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom
US4624251A (en) * 1984-09-13 1986-11-25 Riker Laboratories, Inc. Apparatus for administering a nebulized substance
US4635627A (en) * 1984-09-13 1987-01-13 Riker Laboratories, Inc. Apparatus and method
JPS61130238A (ja) * 1984-11-30 1986-06-18 Res Dev Corp Of Japan 動脈硬化巣認識モノクロナル抗体および反応試薬
US4874795A (en) * 1985-04-02 1989-10-17 Yesair David W Composition for delivery of orally administered drugs and other substances
US4839369A (en) * 1985-04-16 1989-06-13 Rorer Pharmaceutical Corporation Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments
US4690683A (en) * 1985-07-02 1987-09-01 Rutgers, The State University Of New Jersey Transdermal varapamil delivery device
US6019970A (en) * 1985-07-31 2000-02-01 Ghent William R. Treatment of iodine deficiency diseases
EP0302065B1 (de) * 1986-03-21 1994-08-10 Eurasiam Laboratories, Inc. Arzneimittelzusammensetzungen
US6025477A (en) * 1986-03-31 2000-02-15 Calenoff; Emanuel Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
ES2028074T3 (es) * 1986-06-13 1992-07-01 Alza Corporation Activacion por humedad de un sistema de suministro transdermico de farmacos.
CN1093255A (zh) * 1986-06-17 1994-10-12 恩特雷麦德有限公司 抗甾醇疫苗
US5849298A (en) * 1987-06-24 1998-12-15 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of bovine myelin
US5843445A (en) * 1987-06-24 1998-12-01 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
US5399347A (en) * 1987-06-24 1995-03-21 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
US6645504B1 (en) * 1987-06-24 2003-11-11 Autoimmune Inc. Bystander suppression of type I diabetes by oral administration of glucagon
US5110597A (en) * 1987-06-25 1992-05-05 Alza Corporation Multi-unit delivery system
US4917895A (en) * 1987-11-02 1990-04-17 Alza Corporation Transdermal drug delivery device
US4837027A (en) * 1987-11-09 1989-06-06 Alza Corporation Transdermal drug delivery device
BR9007527A (pt) * 1989-07-14 1992-06-23 Autoimmune Inc Metodo para tratar ou prevenir a manifestacao clinica de uma doenca tendo os sintomas de uveoretinite e formulacao farmaceutica para tratar mamiferos sofrendo de uveoretinite
EP0450099B1 (de) * 1989-10-19 1996-09-11 Yamasa Shoyu Kabushiki Kaisha Träger zur bindung von antiphospholipid-antikörpern, diese antikörper verwendender immunotest und kit dafür
US5196324A (en) * 1989-12-15 1993-03-23 Eli Lilly And Company Monoclonal antibodies reactive with a human atheroma associated antigen
US6077509A (en) * 1990-03-30 2000-06-20 Autoimmune, Inc. Peptide fragments of myelin basic protein
WO1991015772A1 (en) * 1990-04-06 1991-10-17 Yamasa Shoyu Co. Ltd. Methods for determining phospholipids and antibodies thereof
US5348945A (en) * 1990-04-06 1994-09-20 Wake Forest University Method of treatment with hsp70
JPH04506415A (ja) * 1990-04-06 1992-11-05 ヤマサ醤油株式会社 リン脂質およびその抗体の測定方法
US5397771A (en) * 1990-05-10 1995-03-14 Bechgaard International Research And Development A/S Pharmaceutical preparation
IL99699A (en) * 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
US5733542A (en) * 1990-11-16 1998-03-31 Haynesworth; Stephen E. Enhancing bone marrow engraftment using MSCS
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
ES2109362T3 (es) * 1991-06-21 1998-01-16 Univ Cincinnati Unas proteinas administrables oralmente y metodo para hacerlas.
DE69322842T2 (de) * 1992-02-05 1999-05-20 Koike, Takao, Sapporo, Hokkaido Festphasenreagenz und selbiges verwendendes antikörpertestverfahren
US6130059A (en) * 1992-03-02 2000-10-10 Covacci; Antonello Helicobacter pylori proteins useful for vaccines and diagnostics
US5807884A (en) * 1992-10-30 1998-09-15 Emory University Treatment for atherosclerosis and other cardiovascular and inflammatory diseases
US5409710A (en) * 1993-04-20 1995-04-25 Endocon, Inc. Foam cell drug delivery
WO1995009363A1 (en) * 1993-09-29 1995-04-06 Yamasa Corporation Method of assaying oxidized lipoprotein and application thereof
ES2110777T3 (es) * 1993-10-01 1998-02-16 Siemens Ag Procedimiento y disposicion para la medicion de una corriente electrica con dos señales luminosas opuestas utilizando el efecto faraday.
US5681571A (en) * 1993-10-08 1997-10-28 Duotol Ab Immunological tolerance-inducing agent
US5998223A (en) * 1993-11-16 1999-12-07 Yamasa Corporation Method of assaying autoimmune anticardiolipin antibody and kit therefor
ES2216009T3 (es) * 1994-03-21 2004-10-16 Rijksuniversiteit Utrecht Fragmentos peptidicos de proteinas de estres microbianas y composicion farmaceutica a base de estos para el tratamiento y la prevencion de enfermedades inflamatorias.
DE4413938A1 (de) * 1994-04-21 1995-11-02 Gerhild Dr Wildner Peptide als Therapeutikum für Autoimmunerkrankungen
US6156500A (en) * 1995-02-10 2000-12-05 Millennium Pharmaceuticals, Inc. Methods for the treatment and diagnosis of cardiovascular disease
US5874409A (en) * 1995-06-07 1999-02-23 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
AU6333796A (en) * 1995-06-07 1996-12-30 Autoimmune, Inc. Oral tolerance in skin diseases presenting with t-cell media ted inflammation
US6410775B1 (en) * 1995-06-07 2002-06-25 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
US5856446A (en) * 1995-07-07 1999-01-05 Autoimmune Inc. Method of treating rheumatoid arthritis with low dose type II collagen
TW460753B (en) * 1995-07-20 2001-10-21 Shinetsu Chemical Co Chemically amplified positive resist material
FR2742989B1 (fr) * 1995-12-29 1998-01-23 Adir Composition pharmaceutique bioadhesive pour la liberation controlee de principes actifs
US5843449A (en) * 1996-03-25 1998-12-01 Akzo Nobel N.V. Proteins and novel peptides derived from autoantigen for use in immunotherapy of autoimmune diseases
US6034102A (en) * 1996-11-15 2000-03-07 Pfizer Inc Atherosclerosis treatment
US6114395A (en) * 1996-11-15 2000-09-05 Pfizer Inc. Method of treating atherosclerosis
US6225070B1 (en) * 1997-08-07 2001-05-01 The Regents Of The University Of California Antibodies to oxidation-specific epitopes on lipoprotein and methods for their use in detecting, monitoring and inhibiting the growth of atheroma
US6019975A (en) * 1997-11-13 2000-02-01 Elizabeth Arden Co., Division Of Conopco, Inc. Antisebum and antioxidant compositions containing a low molecular weight fraction of gugulipid
US5935577A (en) * 1998-01-23 1999-08-10 Autoimmune Inc. Treatment of autoimmune disease using tolerization in combination with methotrexate
US6541011B2 (en) * 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
US5945308A (en) * 1998-04-03 1999-08-31 Incyte Pharmaceuticals, Inc. Human oxidized LDL receptor
US6818213B1 (en) * 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
AU750414B2 (en) * 1998-07-13 2002-07-18 Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
US6309888B1 (en) * 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
US20050197283A1 (en) * 1998-10-04 2005-09-08 Vascular Biogenics Ltd. Compositions containing beta 2-glycoprotein I for the prevention and/or treatment of vascular disease
US20050148499A1 (en) * 1998-10-04 2005-07-07 Dror Harats Compositions containing beta 2-glycoprotein I for the prevention and/or treatment of atherosclerosis
US6812205B2 (en) * 2000-03-15 2004-11-02 The Brigham & Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
US6610713B2 (en) * 2000-05-23 2003-08-26 North Shore - Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
JP4191997B2 (ja) * 2001-01-04 2008-12-03 ヴァスキュラー バイオジェニックス リミテッド アテローム性動脈硬化を防止および処置するために斑関連分子を用いる方法および斑関連分子を含有する組成物
MXPA03008109A (es) * 2001-03-07 2003-12-12 Pfizer Prod Inc Moduladores de la actividad de receptores de quimiocinas.
US20030100036A1 (en) * 2001-11-08 2003-05-29 Aristo Vojdani Saliva immunoassay for detection of antibodies for cardiovascular disease

Also Published As

Publication number Publication date
PT1126867E (pt) 2003-09-30
AU760582B2 (en) 2003-05-15
HUP0104410A2 (hu) 2002-03-28
CN1176716C (zh) 2004-11-24
WO2000020019A2 (en) 2000-04-13
HK1043743A1 (en) 2002-09-27
CA2345445A1 (en) 2000-04-13
JP4834219B2 (ja) 2011-12-14
JP2002526416A (ja) 2002-08-20
ES2198163T3 (es) 2004-01-16
KR20010083886A (ko) 2001-09-03
CN100430090C (zh) 2008-11-05
CA2345445C (en) 2010-08-24
HK1076600A1 (zh) 2006-01-20
US20030114367A1 (en) 2003-06-19
CN1616085A (zh) 2005-05-18
EP1126867B1 (de) 2003-05-14
WO2000020019A3 (en) 2000-06-09
DE69907945D1 (de) 2003-06-18
KR100680707B1 (ko) 2007-02-08
HUP0104410A3 (en) 2004-07-28
CN1332636A (zh) 2002-01-23
DE69907945T2 (de) 2004-03-11
IL126447A (en) 2004-09-27
DK1126867T3 (da) 2003-09-08
EP1126867A2 (de) 2001-08-29
BR9914631A (pt) 2001-07-03
AU5996699A (en) 2000-04-26
IL126447A0 (en) 1999-08-17
US20020025321A1 (en) 2002-02-28

Similar Documents

Publication Publication Date Title
DE69907945D1 (de) Zusammensetzung zur vorbeugung und/oder behandlung der atherosklerose
ATE383169T1 (de) Komponente und zusammensetzungen zur verabreichung von wirkstoffen
ATE218581T1 (de) Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
CY2473B1 (en) New phenanthridines.
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
DE69034148D1 (de) Kombinationstherapie zur Prophylaxe und/oder Behandlung von gutartiger prostatischer Hyperplasie
EA200000994A1 (ru) Применение кабэрголина при лечении синдрома усталых ног
WO1998033491A3 (en) Treatment of arrhythmias via inhibition of a multifunctional calcium/calmodulin-dependent protein kinase
GB9917406D0 (en) Compounds
BG105302A (en) Means for improving cognition
EP1001782A4 (de) 5,6-HETEROARYL-DIPYRIDO (2-3-b:3',2'-f) AZEPINE UND DEREN VERWENDUNG ZUR PROPHYLAXE UND BEHANDLUNG VON HIV-INFEKTIONEN
CY2431B1 (en) Novel phenanthridines substituted in the 6 position.
PL329802A1 (en) Derivatives of androstene
ATE104551T1 (de) S-adenosylmethionin zur behandlung von pankreatitis und der immunabstossung des pankreastransplantates.
ATE212548T1 (de) Behandlung und prophylaxe von pankreatitis
DE69526584D1 (de) Verwendung von immunosuppressiva zur behandlung der schizophrenie
GB9802542D0 (en) New use
ATE269714T1 (de) Tcf-ii für vorbeugung und/oder behandlung von strahlungsinduzierter störungen
ATE361119T1 (de) Prävention und therapie von leberzirrhosen
NZ331374A (en) Phenanthridine compounds and pharmaceutical compositions thereof
DE69838981D1 (de) Komponente und Zusammensetzungen zur Verabreichung von Wirkstoffen
DE58902466D1 (de) Acyl-carnitin zur behandlung und zur verhuetung von virusinfektionen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1126867

Country of ref document: EP